Measuring soluble platelet glycoprotein VI in human plasma by ELISA.
Recent experimental evidence demonstrates that the platelet-specific collagen receptor, glycoprotein (GP)VI is essentially all uncleaved on normal circulating platelets, but is shed from the platelet surface in a metalloproteinase-dependent manner in response to GPVI ligands (including collagen), anti-GPVI antibodies or activation at the platelet Fc receptor, FcgammaRIIa. This raises the question of whether shed ectodomain fragment in plasma could be a useful biomarker of thrombotic risk and/or autoimmune thrombocytopenia. In this study, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) for measuring soluble GPVI in human plasma, using rabbit anti-GPVI polyclonal antibody in the solid-phase, murine anti-GPVI monoclonal antibody (1A12) in the fluid-phase and horseradish peroxidase (HRP)-coupled anti-mouse antibody and enhanced chemiluminescence (ECL) for detection. The ELISA was optimized for sensitivity, reproducibility, inter- and intra-assay precision, addition and recovery and detected GPVI in plasma with a lower detection limit of approximately 1 ng/mL. Effects of different anti-coagulants (trisodium citrate, acid-citrate-dextrose or EDTA) were negligible. In ten healthy donors, soluble plasma GPVI levels were 18.9 +/- 4.1 ng/mL. Treating normal platelet-rich plasma with a GPVI ligand (collagen-related peptide, CRP), calmodulin inhibitor W7 (that induces GPVI shedding without platelet activation) or N-ethylmaleimide (that directly activates platelet sheddases), under conditions previously shown to induce GPVI shedding, also increased plasma GPVI levels by up to approximately 7-fold, compared to previously reported autoimmune (anti-GPVI) patient plasma where soluble GPVI was approximately 10-fold higher than normal. Characterization of this sensitive ELISA should facilitate analysis of functional/diagnostic role(s) for soluble GPVI in human plasma associated with thrombotic/immune dysfunction.
Department of Immunology, Monash University, Alfred Medical Research & Education Precinct, Melbourne, Australia.
Mohammad
M
Al-Tamimi
Fi-Tjen
FT
Mu
Masaaki
M
Moroi
Elizabeth E
EE
Gardiner
Michael C
MC
Berndt
Robert K
RK
Andrews
D000818:Animals; D000906:Antibodies; D000925:Anticoagulants / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D018955:CD36 Antigens / Q000097:blood* / Q000276:immunology; D002147:Calmodulin / Q000037:antagonists & inhibitors; D002352:Carrier Proteins / Q000494:pharmacology; D020536:Enzyme Activators / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005033:Ethylmaleimide / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D010455:Peptides / Q000494:pharmacology; D015539:Platelet Activation; D053657:Platelet-Rich Plasma; D011817:Rabbits; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000494:pharmacology
D000906:Antibodies; D000925:Anticoagulants; D018955:CD36 Antigens; D002147:Calmodulin; D002352:Carrier Proteins; D020536:Enzyme Activators; D010455:Peptides; D013449:Sulfonamides; C435908:collagen-related peptide; C017967:W 7; D005033:Ethylmaleimide